Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships

Drug Testing and Analysis

Volumn 8, Issue 7, 2016, Pages 690-701

  Hartman, Rebecca L ^a,b   Brown, Timothy L ^c   Milavetz, Gary ^c   Spurgin, Andrew ^c   Gorelick, David A ^d   Gaffney, Gary ^e   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF IOWA   (United States)

Author keywords

alcohol; blood; cannabis; oral fluid; subjective

Indexed keywords

BLOOD; COPYRIGHTS;

ALCOHOL CONCENTRATIONS; ALCOHOL INTAKE; BLOOD; CANNABINOIDS; CANNABIS; LOW DOSE; ORAL FLUIDS; SUBJECTIVE; TIME POINTS; VISUAL ANALOG SCALE;

ANALYSIS OF VARIANCE (ANOVA);

ALCOHOL; CANNABINOID; CANNABIS; DRONABINOL; ILLICIT DRUG; PLACEBO;

ADULT; ALCOHOL CONSUMPTION; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; ETHNICITY; FEMALE; GAS CHROMATOGRAPHY; HUMAN; LIKERT SCALE; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; RACE; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; VAPORIZATION; VISUAL ANALOG SCALE;

EID: 84979224602     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1839     Document Type: Article

References (54)

1. ProCon.org. 23 Legal Medical Marijuana States and DC: Laws, Fees, and Possession Limits. Available at: http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881 [Updated 30 October 2014; Accessed 2 December 2014]. 2014.
2. S. Baggio, S. Deline, J. Studer, M. Mohler-Kuo, J. B. Daeppen, G. Gmel. Routes of administration of cannabis used for nonmedical purposes and associations with patterns of drug use. J. Adolesc. Health. 2014, 54, 235.
3. J. E. Joy, S. J. Watson Jr., J. A. Benson Jr. (Eds). Marijuana and Medicine: Assessing the Science Base, National Academy Press, Washington, DC, 1999.
4. A. Hazekamp, R. Ruhaak, L. Zuurman, J. van Gerven, R. Verpoorte. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. J. Pharm. Sci. 2006, 95, 1308.
5. D. I. Abrams, H. P. Vizoso, S. B. Shade, C. Jay, M. E. Kelly, N. L. Benowitz. Vaporization as a smokeless cannabis delivery system: A pilot study. Clin. Pharmacol. Ther. 2007, 82, 572.
6. L. Zuurman, C. Roy, R. Schoemaker, A. Hazekamp, J. den Hartigh, J. Bender, R. Verpoorte, J. Pinquier, A. Cohen, J. van Gerven. Effect of intrapulmonary tetrahydrocannabinol administration in humans. J. Psychopharmacol. 2008, 22, 707.
7. N. T. Van Dam, M. Earleywine. Pulmonary function in cannabis users: Support for a clinical trial of the vaporizer. Int. J. Drug Policy. 2010, 21, 511.
8. B. Pomahacova, F. Van der Kooy, R. Verpoorte. Cannabis smoke condensate III: The cannabinoid content of vaporised Cannabis sativa. Inhal. Toxicol. 2009, 21, 1108.
9. M. Earleywine, S. S. Barnwell. Decreased respiratory symptoms in cannabis users who vaporize. Harm Reduct. J. 2007, 4, 11.
10. R. L. Hartman, M. A. Huestis. Cannabis effects on driving skills. Clin. Chem. 2013, 59, 478.
11. M. B. Johnson, T. Kelley-Baker, R. B. Voas, J. H. Lacey. The prevalence of cannabis-involved driving in California. Drug Alcohol Depend. 2012, 123, 105.
12. Rocky Mountain High Intensity Drug Trafficking Area (RMHIDTA). The Legalization of Marijuana in Colorado: The Impact. 2013, 1, 1. www.rmhidta.org Accessed 5 September 2013.
13. 9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. Drug Alcohol Depend. 2012, 125, 313.
14. M. Fabritius, M. Augsburger, H. Chtioui, B. Favrat, C. Giroud. Fitness to drive and cannabis: Validation of two blood THCCOOH thresholds to distinguish occasional users from heavy smokers. Forensic Sci. Int. 2014, 242C, 1.
15. M. B. Biecheler, J. F. Peytavin, F. Facy, H. Martineau. SAM survey on ‘drugs and fatal accidents’: search of substances consumed and comparison between drivers involved under the influence of alcohol or cannabis. Traffic Inj. Prev. 2008, 9, 11.
16. A. W. Jones, A. Holmgren, F. C. Kugelberg. Driving under the influence of cannabis: a 10-year study of age and gender differences in the concentrations of tetrahydrocannabinol in blood. Addiction. 2008, 103, 452.
17. O. H. Drummer. Drug testing in oral fluid. Clin. Biochem. Rev. 2006, 27, 147.
18. W. M. Bosker, M. A. Huestis. Oral fluid testing for drugs of abuse. Clin. Chem. 2009, 55, 1910.
19. S. M. Wille, V. Di Fazio, S.W. Toennes, J. H. van Wel, J. G. Ramaekers, N. Samyn. Evaluation of Delta 9-tetrahydrocannabinol detection using DrugWipe5S screening and oral fluid quantification after Quantisal collection for roadside drug detection via a controlled study with chronic cannabis users. Drug Test. Anal. 2014. doi: 10.1002/dta.1660
20. O. H. Drummer, D. Gerostamoulos, M. Chu, P. Swann, M. Boorman, I. Cairns. Drugs in oral fluid in randomly selected drivers. Forensic Sci. Int. 2007, 170, 105.
21. T. Van der Linden, S. A. Legrand, P. Silverans, A. G. Verstraete. DUID: oral fluid and blood confirmation compared in Belgium. J. Anal. Toxicol. 2012, 36, 418.
22. M. A. Huestis, A. Verstraete, T. C. Kwong, J. Morland, M. J. Vincent, R. De La Torre. Oral fluid testing: Promises and pitfalls. Clin. Chem. 2011, 57, 805.
23. S. J. Adamson, J. D. Sellman. A prototype screening instrument for cannabis use disorder: the Cannabis Use Disorders Identification Test (CUDIT) in an alcohol-dependent clinical sample. Drug Alcohol Rev. 2003, 22, 309.
24. L. C. Sobell, M. B. Sobell. Alcohol Consumption Measures in Assessing Alcohol Problems: A Guide for Clinicians and Researchers, 2nd Ed, (Eds: J. P. Allen, V. B. Wilson). NIH Pub. No. 03-3745, US Department of Health and Human Services, Bethesda, 2003, 75–99.
25. H. Moskowitz, D. Fiorentino. A review of the literature on the effects of low doses of alcohol on driving-related skills. National Highway Traffic Safety Administration, DOT HS 809 208, 2000.
26. R. L. Hartman, S. Anizan, M. Jang, T. L. Brown, K. Yun, D. A. Gorelick, G. Milavetz, A. Spurgin, G. Gaffney, M. A. Huestis. Cannabinoid disposition in oral fluid after controlled vaporizer administration with and without alcohol. Forensic Toxicol. 2015. DOI:10.1007/s11419-015-0269-6.
27. D. Lee, G. Milman, D. M. Schwope, A. J. Barnes, D. A. Gorelick, M. A. Huestis. Cannabinoid stability in authentic oral fluid after controlled cannabis smoking. Clin. Chem. 2012, 58, 1101.
28. K. B. Scheidweiler, D. M. Schwope, E. L. Karschner, N. A. Desrosiers, D. A. Gorelick, M. A. Huestis. In vitro stability of free and glucuronidated cannabinoids in blood and plasma following controlled smoked cannabis. Clin. Chem. 2013, 59, 1108.
29. G. Milman, A. J. Barnes, R.H. Low, M. A. Huestis. Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry. J. Chrom. A. 2010, 1217, 1513.
30. D. Schwope, K. Scheidweiler, M. Huestis. Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography–tandem mass spectrometry. Anal. Bioanal. Chem. 2011, 401, 1273.
31. R. L. Hartman, T.L. Brown, G. Milavetz, A. Spurgin, D.A. Gorelick, G. Gaffney, M.A. Huestis. Controlled cannabis vaporizer administration: blood and plasma cannabinoids with and without alcohol. Clin. Chem. 2015. 61, 850.
32. J. Ramaekers, E. Theunissen, M. de Brouwer, S. Toennes, M. Moeller, G. Kauert. Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users. Psychopharmacol. 2011, 214, 391.
33. D. M. Schwope, W. M. Bosker, J. G. Ramaekers, D. A. Gorelick, M. A. Huestis. Psychomotor performance, subjective and physiological effects and whole blood Δ9-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis. J. Anal. Toxicol. 2012, 36, 405.
34. M. A. Huestis, A. H. Sampson, B. J. Holicky, J. E. Henningfield, E. J. Cone. Characterization of the absorption phase of marijuana smoking. Clin. Pharmacol. Ther. 1992, 52, 31.
35. C. C. Hunault, K. B. Bocker, R. K. Stellato, J. L. Kenemans, I. de Vries, J. Meulenbelt. Acute subjective effects after smoking joints containing up to 69 mg Delta9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial. Psychopharmacology (Berl). 2014, 231, 4723.
36. J. G. Ramaekers, G. Kauert, P. van Ruitenbeek, E. L. Theunissen, E. Schneider, M. R. Moeller. High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacol. 2006, 31, 2296.
37. J. Ramaekers, G. Kauert, E. Theunissen, S. Toennes, M. Moeller. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J. Psychopharmacol. 2009, 23, 266.
38. C. W. N. Chiang, G. Barnett. Marijuana effect and delta-9-tetrahydrocannabinol plasma level. Clin. Pharmacol. Ther. 1984, 36, 234.
39. M. A. Huestis. Pharmacokinetics and metabolism of the plant cannabinoids, Δ9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb. Exp. Pharmacol. 2005, 168, 657.
40. C. Louizos, J. A. Yanez, M. L. Forrest, N. M. Davies. Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships. J. Pharm. Sci. 2014, 17, 34.
41. D. P. Riff, A. C. Jain, J. T. Doyle. Acute hemodynamic effects of ethanol on normal human volunteers. Am. Heart J. 1969, 78, 592.
42. M. Perez-Reyes, R. E. Hicks, J. Bumberry, A. R. Jeffcoat, C. E. Cook. Interaction between marihuana and ethanol: effects on psychomotor performance. Alcohol. Clin. Exp. Res. 1988, 12, 268.
43. S. E. Lukas, R. Benedikt, J. H. Mendelson, E. Kouri, M. Sholar, L. Amass. Marihuana attenuates the rise in plasma ethanol levels in human subjects. Neuropsychopharmacology. 1992, 7, 77.
44. S. E. Lukas, S. Orozco. Ethanol increases plasma delta-9-tetrahydrocannabinol (THC) levels and subjective effects after marihuana smoking in human volunteers. Drug Alcohol Depend. 2001, 64, 143.
45. M. Fabritius, H. Chtioui, G. Battistella, J. M. Annoni, K. Dao, B. Favrat, E. Fornari, E. Lauer, P. Maeder, C. Giroud. Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint. Anal. Bioanal. Chem. 2013, 405, 9791.
46. K. Langel, H. Gjerde, D. Favretto, P. Lillsunde, E. L. Oiestad, S. D. Ferrara, A. G. Verstraete. Comparison of drug concentrations between whole blood and oral fluid. Drug Test. Anal. 2014, 6, 461.
47. D. Lee, R. Vandrey, G. Milman, M. Bergamaschi, D. R. Mendu, J. A. Murray, A. J. Barnes, M. A. Huestis. Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration. Anal. Bioanal. Chem. 2013, 405, 7269.
48. G. Milman, D. M. Schwope, E. W. Schwilke, W. D. Darwin, D. L. Kelly, R. S. Goodwin, D. A. Gorelick, M. A. Huestis. Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral {Delta}9-tetrahydrocannabinol administration. Clin. Chem. 2011, 57, 1597.
49. S. W. Toennes, K. Schneider, C. Wunder, G. F. Kauert, M. R. Moeller, E. L. Theunissen, J. G. Ramaekers. Influence of ethanol on the pharmacokinetic properties of Delta9-tetrahydrocannabinol in oral fluid. J. Anal. Toxicol. 2013, 37, 152.
50. J. G. Ramaekers, M. R. Moeller, P. van Ruitenbeek, E. L. Theunissen, E. Schneider, G. Kauert. Cognition and motor control as a function of Δ9-THC concentration in serum and oral fluid: Limits of impairment. Drug Alcohol Depend. 2006, 85, 114.
51. G. Kauert, J. Ramaekers, E. Schneider, M. Moeller, S. Toennes. Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid. J. Anal. Toxicol. 2007, 31, 288.
52. S. M. R. Wille, E. Raes, P. Lillsunde, T. Gunnar, M. Laloup, N. Samyn, A. S. Christophersen, M. R. Moeller, K. P. Hammer, A. G. Verstraete. Relationship between oral fluid and blood concentrations of drugs of abuse in drivers suspected of driving under the influence of drugs. Ther. Drug Monit. 2009, 31, 511.
53. H. Gjerde, K. Langel, D. Favretto, A. G. Verstraete. Estimation of equivalent cutoff thresholds in blood and oral fluid for drug prevalence studies. J. Anal. Toxicol. 2014, 38, 92.
54. C. Moore, C. Coulter, D. Uges, J. Tuyay, S. van der Linde, A. van Leeuwen, M. Garnier, J. Orbita Jr. Cannabinoids in oral fluid following passive exposure to marijuana smoke. Forensic Sci. Int. 2011, 212, 227.